Why the study?
Obesity is increasingly prevalent in HFrEF, but whether incretin-based therapies reduce morbidity and mortality or pose safety concerns in these patients remains unaddressed by dedicated trials.
Do GLP-1 receptor agonists reduce morbidity and mortality in patients with HFrEF?
Population
Patients with heart failure with reduced ejection fraction (HFrEF), particularly those with obesity.
Design
Editorial
Key result
Existing data from subgroup analyses do not support safety concerns regarding GLP-1 receptor agonists in HFrEF, highlighting the need for a dedicated prospective randomized trial.
Authors
Loading...
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“These findings offer reassurance that GLP-1 receptor agonists are not only safe for stable patients with HFrEF but may even be helpful in improving long-term clinical outcomes. We look forward to potential validation of these findings in prospective studies.”
Subgroup data indicate no excess HF risk with GLP-1 RAs in HFrEF; challenges prior concerns but leaves open need for dedicated RCTs.
Do GLP-1 receptor agonists reduce morbidity and mortality in patients with HFrEF?
There is a critical need for a dedicated, adequately powered randomized controlled trial to evaluate the safety and efficacy of GLP-1 receptor agonists in patients with HFrEF.
Butt et al. (2025) conducted a review in Heart failure with reduced ejection fraction (HFrEF) and obesity. Glucagon-like peptide 1-receptor agonists (GLP-1 RA) was evaluated. Existing data from subgroup analyses do not support safety concerns regarding GLP-1 receptor agonists in HFrEF, highlighting the need for a dedicated prospective randomized trial.